EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Effectiveness of Colchicine for the Treatment of Long COVID

Abhinav Bassi, Niveditha Devasenapathy, Shani S Thankachen, Arpita Ghosh, Aman Rastogi, Ritika Khan, Bijini Bahuleyan, Balaji Gummidi, Aneesh Basheer, Thekkumkara Prabhakaran Sreelal, Ashfak Bangi, Yasmeen Shaikh und 10 weitere

JAMA Internal Medicine · 2025

DOI: 10.1001/jamainternmed.2025.5408 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, 2025. Verfasst von Abhinav Bassi und 21 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health India, Delhi, India. Hauptthemen laut MEDLINE: Colchicine, COVID-19, COVID-19 Drug Treatment, Anti-Inflammatory Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Long COVID is characterized by persistent symptoms after SARS-CoV-2 infection, with inflammation playing a key role in pathogenesis. Colchicine, an established anti-inflammatory agent, may reduce these symptoms by targeting inflammatory pathways.

Objective

To evaluate the superiority of colchicine over placebo in improving functional outcome at 52 weeks from baseline. Design, Setting, and Participants This double-blind, 1:1 randomized clinical trial recruited participants with confirmed SARS-CoV-2 infection and persistent symptoms from 8 hospitals in 6 states in India between January 2022 and July 2023. Individuals were eligible if they had functional limitation (Post–COVID-19 Functional Status scale grade 2 or more) and/or elevated inflammatory markers (high-sensitivity C-reactive protein >0.20 mg/dL and/or neutrophil to lymphocyte ratio >5). Outcomes were assessed at 12, 26, and 52 weeks after randomization. Data were analyzed from January to February 2025.

Interventions

Participants were randomly assigned to receive colchicine, 0.5 mg, once or twice daily, based on body weight, or placebo for 26 weeks. Main Outcomes and Measures The primary outcome was the change in distance walked during a 6-minute walk test from baseline to 52 weeks. Secondary outcomes included changes in inflammatory markers and patient-reported outcome measures, such as quality of life, anxiety, depression, fatigue, dyspnea, measured using validated instruments.

Results

Of 346 participants included in the modified intention-to-treat analysis, 209 (60.4%) were female, 137 (39.6%) were male, and the mean (SD) age was 46 (12) years. At 52 weeks, there was no difference in mean (SD) change in 6-minute walk test distance between the colchicine and placebo groups (colchicine, 35.5 [19.76] m; placebo, 29.96 [19.83] m; mean difference, 5.59 m; 95% CI, –9.00 to 20.18; P = .45). Similar null findings were seen across all predefined outcomes, except for a small, nonclinically relevant difference in the mean (SD) ratio of forced expiratory volume in 1 second to forced vital capacity (colchicine, −0.02 [0.03]; placebo, −0.06 [0.03]; mean difference, 0.04; 95% CI, 0.02 to 0.07; P = .001). Conclusions and Relevance In this randomized clinical trial, among adults with long COVID, colchicine did not improve functional capacity, respiratory function, or inflammatory markers. These findings underscore the need to explore alternative therapeutic approaches for long COVID. Trial Registration Clinical Trial Registry of India: CTRI/2021/11/038234

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColchicineCOVID-19COVID-19 Drug TreatmentAnti-Inflammatory AgentsHumansMaleFemaleMiddle AgedDouble-Blind MethodAdultSARS-CoV-2Treatment OutcomeQuality of Life

Substanzen

ColchicineAnti-Inflammatory Agents

Autor:innen und Institutionen

  • The George Institute for Global Health India, Delhi, India.
  • The George Institute for Global Health, University of New South Wales, Sydney, Australia.
  • Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.
  • SRM Medical College Hospital and Research Centre, Chennai, India.
  • Department of Community Medicine, Dr Moopen's Medical College, Wayanad, India.
  • Department of General Medicine, Jivenrekha Multispeciality Hospital, Pune, India.

Zitieren

APA

Bassi, A., Devasenapathy, N., Thankachen, S. S., Ghosh, A., Rastogi, A., Khan, R., Bahuleyan, B., Gummidi, B., Basheer, A., Sreelal, T. P., Bangi, A., Shaikh, Y., Sahu, D., Rathore, V., Bhalla, A., Samita, S., Blessan, M., Dipu, T. S., Jain, M., …, & Jha, V. (2025). Effectiveness of Colchicine for the Treatment of Long COVID. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2025.5408

Vancouver

Bassi A, Devasenapathy N, Thankachen SS, Ghosh A, Rastogi A, Khan R, et al. Effectiveness of Colchicine for the Treatment of Long COVID. JAMA Internal Medicine. 2025. doi:10.1001/jamainternmed.2025.5408

BibTeX
@article{Bassi2025,
  author = {Bassi, Abhinav and Devasenapathy, Niveditha and Thankachen, Shani S and Ghosh, Arpita and Rastogi, Aman and Khan, Ritika and Bahuleyan, Bijini and Gummidi, Balaji and Basheer, Aneesh and Sreelal, Thekkumkara Prabhakaran and Bangi, Ashfak and Shaikh, Yasmeen and Sahu, Dibakar and Rathore, Vinay and Bhalla, Ashish and Samita, Samita and Blessan, Merlin and Dipu, T S and Jain, Manish and Prajapati, Abhishek Mukundbhai and Bodhey, Narendra Kuber and Jha, Vivekanand},
  title = {Effectiveness of Colchicine for the Treatment of Long COVID},
  journal = {JAMA Internal Medicine},
  year = {2025},
  doi = {10.1001/jamainternmed.2025.5408}
}
Kostenlos starten →